Table 8 Chemotherapy regimen and overall survival of SCC transformation in MCTO of stage II, III and IV
From: Squamous cell carcinoma transformation in mature cystic teratoma of the ovary: a systematic review
Drug (n = 103) | Univariate HR (95% CI) | P value | Stage-adjusted HR (95% CI) | P value |
|---|---|---|---|---|
Platinum derivatives (n = 92) | 0.43 (0.21–0.87) | 0.02* | 0.41 (0.20–0.84) | 0.02* |
Taxanes (n = 29) | 1.09 (0.61–1.98) | 0.78 | 1.10 (0.60–2.00) | 0.76 |
Vinca alkaloids (n = 21) | 0.59 (0.30–1.20) | 0.14 | 0.48 (0.23–1.01) | 0.05 |
Alkylating agents (n = 15) | 1.05 (0.53–2.09) | 0.88 | 0.84 (0.38–1.84) | 0.66 |
5-FU (n = 16) | 0.77 (0.36–1.62) | 0.50 | 0.82 (0.39–1.75) | 0.61 |
Bleomycin (n = 36) | 0.94 (0.55–1.61) | 0.82 | 0.85 (0.48–1.50) | 0.57 |
VP-16 (n = 12) | 0.76 (0.33–1.78) | 0.53 | 0.82 (0.35–1.92) | 0.64 |